HGEN - Humanigen's partner in South Korea cleared to start early-stage trial for COVID-19 therapy

SvetaZi/iStock via Getty Images Telcon RF Pharmaceutical and KPM Tech, the partners of Humanigen ([[HGEN]] -0.7%) for South Korea and the Philippines, have received the regulatory clearance in South Korea to advance a Phase 1 trial for the company’s experimental COVID-19 therapy, lenzilumab. The randomized, placebo-controlled, double-blind study is expected to involve 20 healthy Korean adults and is designed to evaluate the primary endpoints of the safety, tolerability, and pharmacokinetics of lenzilumab. Telcon and KPM Tech expect to apply for conditional approval of lenzilumab in South Korea for hospitalized COVID-19 patients based on Phase 1 data from the trial and the current data from Humanigen’s Phase 3 LIVE-AIR study for the treatment. In May, Human announced the peer-reviewed publication of LIVE-AIR trial results.

For further details see:

Humanigen’s partner in South Korea cleared to start early-stage trial for COVID-19 therapy